• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

T cell optimization for effective CAR-T cell therapy to refractory esophageal cancer

Research Project

Project/Area Number 19K22655
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 55:Surgery of the organs maintaining homeostasis and related fields
Research InstitutionMie University

Principal Investigator

Kageyama Shinichi  三重大学, 医学系研究科, リサーチアソシエイト (80194695)

Co-Investigator(Kenkyū-buntansha) 宮原 慶裕  三重大学, 医学系研究科, 産学官連携講座教授 (10582083)
加藤 琢磨  三重大学, 医学系研究科, 准教授 (60224515)
Project Period (FY) 2019-06-28 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2020: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2019: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Keywords食道癌 / がん免疫療法 / T細胞治療 / 遺伝子改変T細胞輸注療法 / CAR-T療法 / TCR遺伝子導入T細胞 / CAR-T細胞 / MAGE-A4
Outline of Research at the Start

固形腫瘍(食道癌)に有効なMAGE-A4新規CAR-T療法に用いるT細胞の最適な調製法、選択法、複合的治療(T細胞の代謝改善薬との併用)のためのrationale構築とin vivoモデルによるPOC取得をする。

Outline of Final Research Achievements

To develop a CAR-T therapy for refractory esophageal cancer, we comprehensively analyzed the phenotype, immune function, and transcriptome (including gene expression analysis related to glucose and fat metabolism) of TCR-gene transduced T cells infused in clinical trials to identify factors associated with in vivo persistence and clinical efficacy.
Factors associated with in vivo persistence and clinical efficacy were explored, and subpopulations selected. The CRS (cytokine release syndrome) pathogenesis involved host-derived cytokines after TCR-T infusion and was significantly related to the differentiation traits of infused TCR-T (manufactured T cells). It was also inferred that TCR-T traits (CD39, CD244) and clinical response (CRS, tumor shrinkage) were involved after infusion.

Academic Significance and Societal Importance of the Research Achievements

転移再発食道癌に対する有効な治療手段がないのが現状であるが、近年免疫療法への期待が高い。本研究はT細胞療法の基盤研究であり、新しいCAR-T細胞療法の臨床開発のための基盤研究である。CAR-T細胞療法ではサイトカイン放出症候群を避けながら有効性を向上させることが重要であり、本研究では臨床反応に関連する因子が特定された。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (5 results)

All 2021 2020 2019

All Journal Article (4 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 4 results,  Open Access: 3 results) Presentation (1 results) (of which Invited: 1 results)

  • [Journal Article] Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients2021

    • Author(s)
      Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H.
    • Journal Title

      Cancer Immunol Immunother

      Volume: Online ahead of print Issue: 11 Pages: 3081-3091

    • DOI

      10.1007/s00262-021-02892-w

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours2020

    • Author(s)
      Ishihara Mikiya、Kageyama Shinichi、Miyahara Yoshihiro、Ishikawa Takeshi、Ueda Shugo、Soga Norihito、Naota Hiroaki、Mukai Katsumi、Harada Naozumi、Ikeda Hiroaki、Shiku Hiroshi
    • Journal Title

      BMC Cancer

      Volume: 20 Issue: 1 Pages: 606-606

    • DOI

      10.1186/s12885-020-07098-4

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.2020

    • Author(s)
      Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H.
    • Journal Title

      Cancer Immunol Immunother

      Volume: 69 Issue: 4 Pages: 663-675

    • DOI

      10.1007/s00262-020-02483-1

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.2019

    • Author(s)
      Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H, Sudo A
    • Journal Title

      Oncology Letters

      Volume: 17 Pages: 3937-3943

    • DOI

      10.3892/ol.2019.10044

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] TCR gene-transduced T-cell therapy for sarcoma2021

    • Author(s)
      影山愼一
    • Organizer
      第18回日本臨床腫瘍学会学術集会
    • Related Report
      2020 Research-status Report
    • Invited

URL: 

Published: 2019-07-04   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi